Dr. David McDermott, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Cornell University / New York State Statutory Colleges

  Medical School, 1992

• English

• Spanish

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts National Harbor, MD, USA. 9-13 November 2016, 2016-12-08

• A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma, 2016-09-20

• FCGR Polymorphisms Influence Response to IL-2 in Metastatic Renal Cell Carcinoma, 2016-10-14

• High systemic and tumor-associated IL8 correlates with reduced clinical benefit of PD-L1 blockade, 2020-05-11

• Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSMregistry, 2017-12-19

• Inhibition of hypoxia-inducible factor-2a in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis, 2021-04-22

• Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naive patients with advanced renal cell carcinoma, 2015-11-04

• Expression of T-cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma, 2020-11-20

• Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma, 2018-09-26

• Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2, 2015-11-04

• Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes, 2014-06-18

• Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma, 2016-04-23

• The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC), 2019-12-20

• Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma, 2016-08-30

• Progressive immune dysfunction with advancing disease stage in renal cell carcinoma, 2021-03-11

• The High-Dose Aldesleukin "Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma, 2014-11-25

• Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, 2012-06-02

• Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma, 2019-09-09

• Metabolomic adaptations and correlates of survival to immune checkpoint blockade, 2019-09-25

• Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial, 2018-02-10

• Prospective Analysis of Genetic Polymorphisms and Risk of Recurrence in Renal Cell Cancer, 2012-12-07

• Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma, 2016-11-15

• Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma, 2020-05-29

• Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma, 2016-09-09

• Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial, 2019-08-16

• A phase I study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor targeted therapies, 2016-05-19

• An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0, 2018-05-30

• Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2), 2015-11-04

• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, 2014-11-27

• A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status, 2017-07-18

• Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma, 2016-10-06

• KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1, 2020-11-23

• Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial, 2020-07-09

• Treatment-Free Survival after Immune Checkpoint Inhibitor Therapy vs. Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial, 2021-11-10

• Combining Immune Checkpoint and VEGFR Inhibition in Favorable-risk and Elderly Patients with Metastatic Renal Cell Carcinoma, 2019-12-05

• Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM, 2016-10-29

• From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit, 2022-03-01

• CD8+T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy, 2023-01-03

• Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma, 2022-01-04

• Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study, 2019-03-14

• Angiogenic factor and cytokine analysis among patients treated with adjuvant VEGFR TKIs in resected renal cell carcinoma, 2019-08-30

• Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma, 2015-11-04

• High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates, 2013-11-07

• PD-1 as a potential target in cancer therapy, 2013-07-21

• Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study, 2018-10-22

• Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma, 2016-02-01

• Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma, 2021-02-05

• Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2, 2016-09-30

• A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma, 2023-02-09

• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial, 2014-12-01

• Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma, 2020-09-01

• Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma, 2010-11-15

• Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression, 2017-10-23

• Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma: Updated Results With Long-Term Follow-up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial, 2020-07-16

• Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma, 2020-11-11

• Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma, 2020-03-03

• Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2), 2015-11-04

• Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab, 2015-11-04

• A Phase I/II study to assess the safety and efficacy of pazopanib and pembrolizumab combination therapy in patients with advanced renal cell carcinoma, 2021-04-20

• Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference, 2009-05-15

• Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial, 2021-03-05

• Clinical utility of a blood-based BRAF V600E mutation assay in melanoma, 2014-10-15

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, 2018-02-14

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma, 2016-05-11

• FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer, 2013-07-10

• Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, 2018-06-04

• Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition, 2019-02-18

• Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma, 2017-08-01

• The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2), 2014-03-07

• Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial, 2015-11-26

• Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma, 2015-09-25

• Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab, 2014-03-03

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16